Structure-Guided DOT1L Probe Optimization by Label-Free Ligand Displacement

The DOT1L lysine methyltransferase has emerged as a validated therapeutic target in MLL-rearranged (MLLr) acute leukemias. Although S-adenosylmethionine competitive inhibitors have demonstrated pharmacological proof-of-principle in MLLr-leukemia, these compounds require further optimization to improve cellular potency and pharmacokinetic stability. Limiting DOT1L inhibitor discovery and ligand optimization have been complex biochemical methods often using radionucleotides and cellular methods requiring prolonged culture. We therefore developed a new suite of assay technologies that allows comparative assessment of chemical tools for DOT1L in a miniaturized format. Coupling these assays with structural information, we developed new insights into DOT1L ligand binding and identified several functionalized probes with increased cellular potency (IC50 values ∼10 nM) and excellent selectivity for DOT1L. Together these assay technologies define a platform capability for discovery and optimization of small-molecule DOT1L inhibitors.

[1]  William B. Smith,et al.  Genome-wide localization of small molecules , 2013, Nature Biotechnology.

[2]  Robert A Copeland,et al.  Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. , 2013, Blood.

[3]  S. Armstrong,et al.  Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. , 2013, Blood.

[4]  Y. Yao,et al.  Synthesis, Activity and Metabolic Stability of Non-Ribose Containing Inhibitors of Histone Methyltransferase DOT1L. , 2013, MedChemComm.

[5]  M. Goodell.  Epigenetics in hematology: introducing a collection of reviews. , 2013, Blood.

[6]  Matthieu Schapira,et al.  Bromo-deaza-SAH: a potent and selective DOT1L inhibitor. , 2013, Bioorganic & medicinal chemistry.

[7]  S. Armstrong,et al.  Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. , 2013, Blood.

[8]  Matthieu Schapira,et al.  Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors , 2012, Nature Communications.

[9]  Yuan Yao,et al.  Synthesis and Structure−Activity Relationship Investigation of Adenosine-Containing Inhibitors of Histone Methyltransferase DOT1L , 2022 .

[10]  Yusuke Murayama,et al.  Unravelling cerebellar pathways with high temporal precision targeting motor and extensive sensory and parietal networks , 2012, Nature Communications.

[11]  Yuan Yao,et al.  Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies. , 2011, Journal of the American Chemical Society.

[12]  Lars Bullinger,et al.  MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. , 2011, Cancer cell.

[13]  Yonghong Xiao,et al.  Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. , 2011, Cancer cell.

[14]  Yi Zhang,et al.  DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. , 2011, Blood.

[15]  Dafydd G. Thomas,et al.  Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. , 2011, Blood.

[16]  James E. Bradner,et al.  Chemical Phylogenetics of Histone Deacetylases , 2010, Nature chemical biology.

[17]  K. Chiang,et al.  Structure-activity analysis of semisynthetic nucleosomes: mechanistic insights into the stimulation of Dot1L by ubiquitylated histone H2B. , 2009, ACS chemical biology.

[18]  Richard A Young,et al.  Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. , 2008, Genes & development.

[19]  Xiaobo Xia,et al.  H3K79 methylation profiles define murine and human MLL-AF4 leukemias. , 2008, Cancer cell.

[20]  Christopher R. Vakoc,et al.  DOT1L/KMT4 Recruitment and H3K79 Methylation Are Ubiquitously Coupled with Gene Transcription in Mammalian Cells , 2008, Molecular and Cellular Biology.

[21]  Scott A. Armstrong,et al.  MLL translocations, histone modifications and leukaemia stem-cell development , 2007, Nature Reviews Cancer.

[22]  Fluorous-based small-molecule microarrays for the discovery of histone deacetylase inhibitors. , 2007, Angewandte Chemie.

[23]  K. Davies,et al.  The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. , 2007, Human molecular genetics.

[24]  Yi Zhang,et al.  hDOT1L Links Histone Methylation to Leukemogenesis , 2005, Cell.

[25]  M. Jansen,et al.  Synthesis and structure of Na3N. , 2002, Angewandte Chemie.

[26]  W. Cullen,et al.  The synthesis and structure of , 1987 .